common.study.topics.clinical

The Metformin Active Surveillance Trial (MAST) Study

common.study.values.description

The Metformin Active Surveillance Trial (MAST) Study

This study aims to see if metformin can delay the time to progression in men with low risk prostate cancer when compared to a placebo.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Metformin

One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.

Drug - Placebo

One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study

common.study.values.clinical-trial-id

NCT01864096

participant.views.study.view.id

1aKLrb